NOIDA, India, June 11 /PRNewswire/ --
- Collaboration to Provide Endo Pharmaceuticals With New Drug Candidates in Oncology
Jubilant Organosys Ltd., headquartered in Noida, announced today that its Bangalore-based subsidiary, Jubilant Biosys Ltd., has entered into a discovery and development collaboration with Endo Pharmaceuticals, a US-based pharmaceutical company. As part of the agreement, Jubilant and Endo would collaborate initially to develop a portfolio of targets in the area of oncology, with a focus on delivering preclinical candidates that could be selected for joint clinical development.
Endo will own any compounds developed under the collaboration and will be responsible for worldwide commercialization.
Under an initial three-year agreement, Jubilant will receive from Endo research funding and success-based development milestones and royalties on the successful commercialization of the compounds developed.
Endo Pharmaceuticals, is a specialty pharmaceutical company engaged in R&D, sales and marketing of branded and generic medicines in pain management, urology, endocrinology and oncology.
Commenting on the Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: "We are pleased to announce this collaboration with Endo Pharmaceuticals, and look forward to the prospect of contributing to Endo's expanding discovery pipeline. We anticipate significant rewards on successful development of compounds and its subsequent commercialization. This partnership continues to demonstrate Jubilant's mission to be India's largest provider of innovative solutions for accelerating global drug development and enabling affordable patient care."
Dr. Ivan Gergel M.D., Executive Vice President, Research & Development of
Endo Pharmaceuticals sai
|SOURCE Jubilant Organosys Ltd|
Copyright©2009 PR Newswire.
All rights reserved